All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
What does real-world data tell us about frontline treatment strategies for MCL?
Featured:
Michael Wang
Peter MartinDuring the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Michael Wang, MD Anderson Cancer Center, Houston, US, and Peter Martin, Weill Cornell Medicine, New York, US. We asked, What does real-world data tell us about frontline treatment strategies for mantle cell lymphoma (MCL)?
What does real-world data tell us about frontline treatment strategies for MCL?
To answer this question, Martin firstly evaluates data from a retrospective study, which included adult patients with MCL in the nationwide Flatiron Health EHR-derived deidentified database. He describes the results in 3,455 previously untreated patients, including treatment patterns in real-world clinical practice and how they compare with clinical studies, patient outcomes, and the role of stem cell transplantation. Wang then shares his opinion on these data, focusing on the time gap between frontline clinical data and changes to practice patterns. He also outlines further data on promising novel regimens for patients with MCL.